Rankings
▼
Calendar
VRDN FY 2023 Earnings — Viridian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
VRDN
Viridian Therapeutics, Inc.
$3B
FY 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$314,000
-82.3% YoY
Gross Profit
$314,000
100.0% margin
Operating Income
-$254M
-81035.0% margin
Net Income
-$238M
-75711.5% margin
EPS (Diluted)
$-5.31
Cash Flow
Operating Cash Flow
-$184M
Free Cash Flow
-$185M
Stock-Based Comp.
$67M
Balance Sheet
Total Assets
$490M
Total Liabilities
$48M
Stockholders' Equity
$442M
Cash & Equivalents
$103M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$314,000
$2M
-82.3%
Gross Profit
$314,000
$2M
-82.3%
Operating Income
-$254M
-$134M
-89.5%
Net Income
-$238M
-$130M
-83.0%
← Q4 2022
All Quarters
Q1 2023 →